Cargando…
Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
BACKGROUND AND OBJECTIVE: Though there are many advantages of pegylated interferon‐α (PegIFN‐α) treatment to chronic hepatitis B (CHB) patients, the response rate of PegIFN‐α is only 30 ~ 40%. Therefore, it is important to explore predictors at baseline and establish models to improve the response r...
Autores principales: | Shang, Hongyan, Hu, Yuhai, Guo, Hongyan, Lai, Ruimin, Fu, Ya, Xu, Siyi, Zeng, Yongbin, Xun, Zhen, Liu, Can, Wu, Wennan, Guo, Jianhui, Ou, Qishui, Chen, Tianbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701889/ https://www.ncbi.nlm.nih.gov/pubmed/36181316 http://dx.doi.org/10.1002/jcla.24667 |
Ejemplares similares
-
Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function
por: Xun, Zhen, et al.
Publicado: (2021) -
The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone
por: Lin, Sheng, et al.
Publicado: (2020) -
Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015) -
Toll‐like receptors, long non‐coding RNA NEAT1, and RIG‐I expression are associated with HBeAg‐positive chronic hepatitis B patients in the active phase
por: Zeng, Yongbin, et al.
Publicado: (2019) -
HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)